CClinicalTrials.gg
Sign In
TerminatedNCT07000630Updated Mar 11, 2026

Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis

An interventional study of Deucravacitinib in Palmoplantar Pustulosis, sponsored by Peking University First Hospital. Terminated at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Peking University First Hospital · Not applicable, Interventional, and Treatment

Why this study was terminated
Terminated early due to lack of expected efficacy. Three participants were enrolled but none completed the study.
Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to investigate the efficacy and safety of Deucravacitinib in patients with moderate-to-severe palmoplantar pustulosis. Approximately 25 subjects will be included in the study and receive Deucravacitinib 6mg per day for four months. This study will begin June 2025 and is expected to last 14 months.

02

Conditions studied

  • Palmoplantar Pustulosis

Browse trials for

Keywords

  • Palmoplantar pustulosis
  • Deucravacitinib
03

In context

Psoriasis

1,899 studies on the registry are indexed under Psoriasis; 233 are open to participants now.

This study's enrollment of 3 is below the median of 70 across 1,447 interventional studies indexed under Psoriasis.

Browse Psoriasis studies →

Lead sponsor

Peking University First Hospital is the lead sponsor of 378 studies on the registry; 178 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Men and women between ages 18 - 65 years who have suffered from palmoplantar pustulosis (PPP) for at least 6 months.
  • Patients were required to have over 10 well-demarcated white or yellow pustules across all regions, with or without plaque psoriasis
  • Patients were required to have a Palmoplantar Pustular Physician's Global Assessment (PPPGA) score of at least moderate severity (≥3) and a minimum PPPASI score of 12.
  • Signed and dated written informed consent in accordance with ICH GCP and local legislation prior to admission to the trial.
  • Further criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Systemic treatment for PPP ended less than five half-lives or 12 weeks ago
  • Topical treatment for PPP ended less 4 weeks ago
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
  • Severe, progressive, or uncontrolled condition such as renal, hepatic, haematological, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease, or signs and symptoms thereof.
  • Presence or known history of anti-TNF-induced PPP-like disease.
  • Patient with a transplanted organ (with exception of a corneal transplant >12 weeks Prior to screening) or who have ever received stem cell therapy.
  • Known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.
  • Further criteria apply.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Deucravacitinib treatment

    25 subjects with palmoplantar pustulosis will be allocated to receive oral Deucravacitinib 6mg everyday for 16 weeks.

    Drug: Deucravacitinib

Interventions

  • DrugDeucravacitinib

    25 subjects with palmoplantar pustulosis will be allocated to receive oral Deucravacitinib 6mg everyday for 16 weeks.

06

What researchers measure

Primary outcomes

  1. Primary efficacy endpoint

    The primary efficacy endpoint was percentage change from baseline in Palmoplantar Pustular Area and Severity Index (PPPASI) at W16.

    Time frame: From enrollment to the end of treatment at 16 weeks

Secondary outcomes

  1. Effect of Deucravacitinib on overall severity of palmoplantar pustulosis

    Mean change in erythema and pustules from Baseline to week 16 will be evaluated by Palmoplantar Pustular Physician's Global Assessment (PPPGA).

    Time frame: From enrollment to the end of treatment at 16 weeks

  2. Effect of Deucravacitinib on quality of life: Dermatology Life Quality Index (DLQI)

    Mean change in quality of life from Baseline to week 16 will be evaluated by Dermatology Life Quality Index (DLQI)

    Time frame: From enrollment to the end of treatment at 16 weeks

Other outcomes

  1. Tolerability of Deucravacitinib in patients with palmoplantar pustulosis

    To evaluate the tolerability of Deucravacitinib in patients with palmoplantar pustulosis through assessment of adverse events at every visit from Baseline to week 4, 8,12, 16.

    Time frame: From enrollment to the end of treatment at 16 weeks

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, 100034, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07000630
Lead sponsor
Peking University First Hospital
Responsible party
Jingru Sun (Attending doctor, Peking University First Hospital) — Principal investigator
First posted
Jun 3, 2025
Start date
Jun 20, 2025
Primary completion
Nov 30, 2025
Completion
Dec 1, 2025
Last update
Mar 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Psoriasis→

Other studies from this sponsor

Peking University First Hospital

Start the discussion